Outcome of Allogeneic Peripheral Blood Stem Cell Transplantation by Donor Graft CD3+/Tregs Ratio: A Single-Center Experience

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 3, 2013, Pages 495-499

  Delia, Mario ^a   Pastore, Domenico ^a   Mestice, Anna ^a   Carluccio, Paola ^a   Perrone, Tommasina ^a   Gaudio, Francesco ^a   Ricco, Alessandra ^a   Sgherza, Nicola ^a   Albano, Francesco ^a   Specchia, Giorgina ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Survival; Tregs content

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CD3+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NON RELAPSE MORTALITY; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; REGULATORY T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIGENS, CD3; FEMALE; GRAFT VS LEUKEMIA EFFECT; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIBLINGS; SURVIVAL ANALYSIS; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84873727657     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.11.015     Document Type: Article

References (32)

1. Nguyen V.H., Shashidhar S., Chang S.D., et al. The impact of regulatory T cells on T-cell immunity following hemtopoietic cell transplantation. Blood 2008, 11:945-953.
2. Edinger M., Hoffmann P., Ermann J., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
3. Dulude G., Roy D.C., Perralut C. The effect of graft-versus-host disease on T cell production and homeostasis. J Exp Med 1999, 189:1329-1342.
4. Wall D.A., Hamberg S.D., Reynolds D.S., et al. Immunodeficiency in graft-versus-host disease: mechanism of immune suppression. J Immunol 1988, 140:2970-2976.
5. Ferrara J.L., Levy R., Chao N.J. Pathophysiologic mechanisms of graft-versus-host-disease. Biol Blood Marrow Transplant 1999, 5:347-356.
6. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft-versus-host disease by inactivation of host antigen presenting cells. Science 1999, 285:412-415.
7. Miura Y., Thoburn C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with acute graft-versus-host disease. Blood 2004, 104:2187-2193.
8. Hess A.D. Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 2006, 12:13-21.
9. Pastore D., Delia M., Mestice A., et al. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2012, 18:887-893.
10. Hoffmann P., Ermann J., Edinger M., et al. Donor-type CD4+CD25+ regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002, 196:389-399.
11. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4+/CD25+ immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
12. Mackall C.L., Gress R.E. Thymic aging and T-cell regeneration. Immunol Rev 1997, 160:91-102.
13. Martin P.J., Hansen C.D., Buckner C.D., et al. Effects on in vitro depletion of T cells in HLA-identical allogeneic marrow graft. Blood 1985, 66:664-672.
14. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75:555-562.
15. Jagasia M., Arora M., Flowers M.E.D., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
16. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.
17. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow HLA matched sibling donors. Transplantation 1974, 18:295-304.
18. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
19. Pastore D., Delia M., Mestice A., et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011, 17:550-557.
20. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer 2009, 115:4715-4726.
21. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
22. Raimondi R., Tosetto A., Oneto R., et al. Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 2012, 120:1327-1333.
23. Eisner M.D., August C.S. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995, 15:663-668.
24. Deeg H.J. How I treat refractory acute GVHD. Blood 2007, 109:4119-4126.
25. Van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 2006, 107:4177-4181.
26. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 1991, 77:1821-1828.
27. Arai S., Margolis J., Zahurak M., et al. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002, 8:55-60.
28. Weiden P.L., Flournoy N., Thomas E.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 1979, 300:1068-1073.
29. Weisdorf D., Zhang M.J., Arora M., et al. Graft-versus-Host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant 2012, 18:1727-1733.
30. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
31. Wolf D., Wol A.M., Fong D., et al. Regulatory T-cells in the graft and the risk of acute graft-versus-host disease after allogeneic stem cell. Transplantation 2007, 83:1107-1113.
32. Fricke S., Rothe K., Hilger N., et al. Allogeneic bone marrow grafts with high levels of CD4+CD25+FoxP3+T cells can lead to engraftment failure. Cytometry Part A 2012, 81:476-488.